A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma

Nucleic Acid Therapeutics - United States
doi 10.1089/nat.2016.0621
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

Stabilized, Cholecystokinin B Receptor (CCKBR; CCK2R)-targeting Radiopeptide for Tumor Imaging

Science-Business eXchange
2011English

Molecular Targeting of Cell-Permeable Peptide Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation

Oncotarget
Oncology
2017English

Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma With a GQuadruplex-Binding Small Molecule

English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma With a GQuadruplex-Binding Small Molecule

English

Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma With a GQuadruplex-Binding Small Molecule

English

Targeting of a Cholecystokinin–DNA Complex to Pancreatic Cells in Vitro and in Vivo

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
1998English

Targeting the Prohibitin Scaffold-Craf Kinase Interaction in RAS-ERK-driven Pancreatic Ductal Adenocarcinoma

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy